106 related articles for article (PubMed ID: 6094685)
21. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
Lynch TJ
Chest; 1993 Apr; 103(4 Suppl):436S-439S. PubMed ID: 8384975
[TBL] [Abstract][Full Text] [Related]
22. Regulation of natural and antibody-dependent cellular cytotoxicity by staphylococcal enterotoxin A.
Kimber I; Bakács T; Moore M
Clin Exp Immunol; 1983 Oct; 54(1):39-48. PubMed ID: 6616973
[TBL] [Abstract][Full Text] [Related]
23. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human natural killer cell activity by the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine is an early but post-binding event.
Steele TA; Brahmi Z
J Immunol; 1988 Nov; 141(9):3164-9. PubMed ID: 3262683
[TBL] [Abstract][Full Text] [Related]
25. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
27. Immune-enhancing effect of recombinant human interferon-beta produced in Escherichia coli on human peripheral blood mononuclear cells in vitro.
Okabe M; Morimoto M; Nakamizo N
Gan; 1983 Oct; 74(5):743-50. PubMed ID: 6357933
[TBL] [Abstract][Full Text] [Related]
28. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with primary lung cancer.
Kim SK; Cho CH; Ahn CM; Jang SH; Lee YH; Kim SK; Chang J; Lee BK; Kim SJ; Youn JK
Yonsei Med J; 1992 Mar; 33(1):41-7. PubMed ID: 1502829
[TBL] [Abstract][Full Text] [Related]
29. Regulation of natural killer cytotoxicity by Escherichia coli-derived human interferon gamma.
Platsoucas CD
Scand J Immunol; 1986 Jul; 24(1):93-108. PubMed ID: 3088722
[TBL] [Abstract][Full Text] [Related]
30. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.
Uchida A; Yanagawa E; Kokoschka EM; Micksche M; Koren HS
Br J Cancer; 1984 Oct; 50(4):483-92. PubMed ID: 6237664
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.
Vuist WM; Visseren MJ; Otsen M; Bos K; Vyth-Dreese FA; Figdor CG; Melief CJ; Hekman A
Cancer Immunol Immunother; 1993; 36(3):163-70. PubMed ID: 8439976
[TBL] [Abstract][Full Text] [Related]
32. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):528-39. PubMed ID: 6363630
[TBL] [Abstract][Full Text] [Related]
33. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
[TBL] [Abstract][Full Text] [Related]
34. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome.
Kerndrup G; Meyer K; Ellegaard J; Hokland P
Leuk Res; 1984; 8(2):239-47. PubMed ID: 6717064
[TBL] [Abstract][Full Text] [Related]
35. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
36. Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2.
Hirsch RL; Johnson KP
Clin Immunol Immunopathol; 1985 Nov; 37(2):236-44. PubMed ID: 3899434
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cell activity in the rat. VI. Characterization of rat large granular lymphocytes as effector cells in natural killer and antibody-dependent cellular cytotoxic activities.
Fukui H; Overton WR; Herberman RB; Reynolds CW
J Leukoc Biol; 1987 Feb; 41(2):130-42. PubMed ID: 2433376
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
Loubeau M; Ahmad A; Toma E; Menezes J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
[TBL] [Abstract][Full Text] [Related]
40. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
